Sector portfolio · Investment firm · United States

National Institute of Allergy and Infectious Diseases' Biotech portfolio

National Institute of Allergy and Infectious Diseases has backed 28 Biotech startups in rounds we track, $407M between them, shown by the stage each has reached. The best-funded is Iliad Biotechnologies.

28startups backed
4stages
$407Mraised between them
Stage not reportedbiggest stage

National Institute of Allergy and Infectious Diseases's profile

Stage not reported

22

Series A

2

Series C and later

2

Series B

2

Segment by segment

Stage not reported

22 startups · $184M raised

  1. Antibacterial Resistance Leadership Group (ARLG)Antibacterial Resistance Leadership Group (ARLG) is a research network for which the Duke Clinical Research InstituteUnited States$103M
  2. ReAlta Life SciencesReAlta is a clinical-stage biotech company that develops a new class of drugs to address life-threatening diseases.United States$40M
  3. Institute for Bioscience and Biotechnology ResearchIBBR is leverages state-of-art integrative methods for bioanalytical, biophysical and structural characterization of biomolecules.United States$6.9M
  4. EtubicsEtubics Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington, founded in 2003.United States$4.4M
  5. Blacksmith MedicinesBlacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.United States$3.3M
  6. Aldatu BiosciencesAldatu Biosciences is the leader in adaptive PCR diagnostics for global health and emerging diseases.United States$3.0M
  7. Exavir TherapeuticsExavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.United States$3.0M
  8. OmnioseOmniose is an early stage biotechnological company.United States$3.0M

Series A

2 startups · $40M raised

  1. Forge TherapeuticsForge Therapeutics is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry.United States$21M
  2. TFF PharmaceuticalsTFF Pharmaceuticals is a clinical-stage biopharmaceutical company that develops drug products.United States$19M

Series C and later

2 startups · $128M raised

  1. ILiAD BiotechnologiesILiAD Biotechnologies, LLC is a clinical-stage biotechnology company based in Weston, Florida, focused on the prevention and treatUnited States$116M
  2. Siolta TherapeuticsSiolta Therapeutics, Inc.United States$12M

Series B

2 startups · $55M raised

  1. OsivaxOsivax is a clinical stage biotechnology company developing a pipeline of vaccines and immunotherapies.France$39M
  2. InDevRInDevR develops and manufactures microarray technologies as well as novel solutions to support the life science industry.United States$16M

How this map is made. Every startup here works in Biotech and has raised money in a round we track that names National Institute of Allergy and Infectious Diseases as an investor. Each sits under the stage of its latest round. Rebuilt nightly; updated 15 November 2026.

More portfolio maps

All portfolios
Sector portfolioNational Cancer Institute (NCI)'s Biotech portfolio34 startups · $361MSector portfolioMayo Clinic's Healthtech portfolio22 startups · $2.1BSector portfolioMayo Clinic's Biotech portfolio19 startups · $479MSector portfolioAVP's AI portfolio17 startups · $1.1BSector portfolioSquare 1 Bank's Biotech portfolio14 startups · $1.6BSector portfolioMayo Clinic's AI portfolio13 startups · $256M

Raising from investors like National Institute of Allergy and Infectious Diseases?

Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.

Find investorsMarket maps